eThe bc 1 complex is central to mitochondrial bioenergetics and the target of the antimalarial drug atovaquone that binds in the quinol oxidation (Q o ) site of the complex. Structural analysis has shown that the Q o site residue Y279 (Y268 in Plasmodium falciparum) is key for atovaquone binding. Consequently, atovaquone resistance can be acquired by mutation of that residue. In addition to the probability of amino acid substitution, the level of atovaquone resistance and the loss of bc 1 complex activity that are associated with the novel amino acid would restrict the nature of resistance-driven mutations occurring on atovaquone exposure in native parasite populations. Using the yeast model, we characterized the effect of all the amino acid replacements resulting from a single nucleotide substitution at codon 279: Y279C, Y279D, Y279F, Y279H, Y279N, and Y279S (Y279C, D, F, H, N, and S). Two residue changes that required a double nucleotide substitution, Y279A and W, were added to the series. We found that mutations Y279A, C, and S conferred high atovaquone resistance but decreased the catalytic activity. Y279F had wild-type enzymatic activity and sensitivity to atovaquone, while the other substitutions caused a dramatic respiratory defect. The results obtained with the yeast model were examined in regard to atomic structure and compared to the reported data on the evolution of acquired atovaquone resistance in P. falciparum.
The mitochondrial respiratory chain complex III or bc 1 complex is central to mitochondrial bioenergetics and the target of antiprotozoals, such as atovaquone, and fungicidal drugs used to control human and plant pathogens. It is also currently the focus of intense research as an antimalarial target for further drug development (1-6). The bc 1 complex is a multimeric enzyme. Three subunits form the electron-transferring catalytic core and contain the redox-active groups, namely, cytochromes b, cytochrome c 1 , and the "Rieske" iron-sulfur protein (ISP). Cytochrome b is mitochondrially encoded in all eukaryotes and contains the substrate ubiquinol/ubiquinone binding sites (i.e., the quinol oxidation [Q o ] and quinone reduction [Q i ] sites), which form the sites of competitive inhibition for antimicrobial agents. In the context of malaria, atovaquone (used in combination with proguanil, and marketed as Malarone) is a popular prophylactic drug and also shows high efficiency in the treatment of uncomplicated Plasmodium falciparum malaria.Interestingly, atovaquone resistance frequently evolves through de novo cytochrome b mutations during antimalarial therapy (7-10). The resistance is caused by the mutation of residue Y279 (Y268 in P. falciparum numbering) in the atovaquone target site, the bc 1 complex Q o site. Y279 is a highly conserved residue. It is crucial for stabilizing the bound atovaquone (11) and is postulated to play a key role in the binding and correct positioning of the ubiquinol in the Q o site, facilitating a fast electron transfer to the [2Fe-2S] cluster of the ISP (12, 13).In...